Overview

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Anastrozole
Gefitinib